Globus Medical, Inc. $GMED Shares Sold by Inceptionr LLC

Inceptionr LLC cut its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 70.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,761 shares of the medical device company’s stock after selling 6,449 shares during the period. Inceptionr LLC’s holdings in Globus Medical were worth $238,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Annex Advisory Services LLC purchased a new stake in shares of Globus Medical during the fourth quarter worth approximately $20,572,000. Northwestern Mutual Wealth Management Co. raised its holdings in Globus Medical by 71,618.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 716,469 shares of the medical device company’s stock valued at $62,555,000 after acquiring an additional 715,470 shares in the last quarter. Lecap Asset Management Ltd. purchased a new position in Globus Medical in the fourth quarter worth approximately $1,203,000. SG Americas Securities LLC lifted its stake in Globus Medical by 241.1% in the first quarter. SG Americas Securities LLC now owns 340,452 shares of the medical device company’s stock worth $29,333,000 after acquiring an additional 240,642 shares during the last quarter. Finally, Artemis Investment Management LLP grew its holdings in Globus Medical by 43.7% during the 4th quarter. Artemis Investment Management LLP now owns 738,595 shares of the medical device company’s stock worth $64,487,000 after acquiring an additional 224,587 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insiders Place Their Bets

In related news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at $41,201,733. This represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 18.38% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on GMED shares. Wall Street Zen downgraded shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Truist Financial decreased their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Piper Sandler dropped their target price on Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a report on Monday, June 15th. Finally, BMO Capital Markets initiated coverage on Globus Medical in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Globus Medical Stock Performance

GMED opened at $80.49 on Wednesday. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The stock has a market capitalization of $10.93 billion, a P/E ratio of 18.72, a price-to-earnings-growth ratio of 1.62 and a beta of 0.95. The business’s 50-day simple moving average is $79.79 and its 200-day simple moving average is $85.85.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company’s revenue was up 27.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.